ImmuCell (ICCC) Akcija Цена

ImmuCell Цена

NASDAQ·ZATVORENO
11,42
​
Tržište je zatvoreno

Prihod je rastao 9,7 % godišnje u poslednjih 19 godina na 27,64 М USD. Zarada po akciji padala je 7,3 % godišnje u poslednjih 10 godina. neto marža kompanije ImmuCell sada iznosi -3,8 %, pala sa -0,4 % pre nekoliko godina.

Cena akcije ImmuCell

Pristupite ovim podacima preko Eulerpool API-ja

100.000 zahteva/mes. besplatno · bez kartice

ImmuCell poslovni model i analiza akcije

ImmuCell Corp je američka kompanija koja se specijalizovala za razvoj i marketing veterinarskih proizvoda za preživače. Osnovana je krajem 1970-ih pod nazivom PrioGene, sa početnim fokusom na razvoj dijagnostike za tuberkulozu i brucelozu kod goveda. Tokom 1990-ih, kompanija je promenila ime u ImmuCell i preusmerila fokus na razvoj proizvoda koji podržavaju zdravlje životinja. Poslovni model ImmuCell-a zasnovan je na razvoju, proizvodnji i prodaji proizvoda za unapređenje zdravlja životinja. Nudi širok spektar veterinarskih proizvoda, uključujući imunološke testove, vakcine, antibiotike i komplementarne hranive. Kompanija teži poboljšanju zdravlja životinja uz minimalan uticaj na životnu sredinu i usko sarađuje sa veterinarima i stručnjacima iz industrije. Poseduje odeljenja posvećena dijagnostici, vakcinama i antibioticima, a njihovi proizvodi pomažu u identifikaciji i sprečavanju bolesti stoke. Istaknuti proizvodi uključuju dijagnostički test LBC za mastitis i Immu-PRIME sprej za sprečavanje infekcija pupka kod novorođenih teladi. ImmuCell se etablirala kao vodeći inovator u industriji zdravlja životinja i sprovela je kliničke studije o efikasnosti svog proizvoda HO-VAX. Zaključno, ImmuCell se fokusira na razvoj i marketing proizvoda koji podržavaju zdravlje životinja, sa posvećenošću poboljšanju blagostanja stoke.

Često postavljana pitanja o akciji ImmuCell

ImmuCell Corp operates as a biotechnology company, focusing on the development and commercialization of products that improve the health and productivity of dairy and beef cattle. The company's business model revolves around providing innovative animal health solutions, such as First Defense® for newborn calves, which helps strengthen their immune system and prevent diseases. ImmuCell Corp also offers Mast Out®, an FDA-approved treatment for mastitis in lactating dairy cows. Through its dedication to science-driven research and development, ImmuCell Corp aims to enhance animal well-being, increase farmers' efficiency, and ultimately contribute to a sustainable agriculture industry.

ImmuCell Corp is primarily active in the animal health industry.

The main competitors of ImmuCell Corp in the market include companies such as Zoetis Inc., Elanco Animal Health Inc., and Merck & Co. Inc.

ImmuCell Corp is a renowned biotechnology company specializing in the development and production of innovative, preventative animal health products, focusing primarily on the dairy and beef industries. Founded in 1982 and headquartered in Portland, Maine, ImmuCell has established itself as a leader in the field of animal health through its dedication to improving the well-being and productivity of livestock. The company's flagship product, First Defense®, helps protect newborn calves against common diseases while enhancing their natural immune system. ImmuCell Corp remains committed to research and development, continuously striving to provide cutting-edge solutions for animal health challenges.

ImmuCell Corp has achieved significant milestones in its history. One of the notable accomplishments is the development and commercialization of their flagship product, First Defense®. This groundbreaking product has revolutionized the field of animal health by providing a proactive approach to preventing calf scours. Additionally, ImmuCell Corp has successfully expanded its product portfolio to include prominent offerings such as Wipe Out® Dairy Wipes and California Mastitis Test. The company's commitment to research and innovation has garnered recognition, including the prestigious "Best Places to Work in Maine" award. ImmuCell Corp continues to make strides in the animal health industry, solidifying its position as a leader in innovative solutions that enhance herd productivity and profitability.

ImmuCell Corp is primarily present in the United States.

ImmuCell Corp represents a set of core values and a corporate philosophy aimed at advancing animal health and well-being. The company is committed to developing, manufacturing, and selling products that enhance the health and productivity of animals, with a specific focus on the dairy and beef industries. ImmuCell prioritizes quality, innovation, and sustainability, striving to provide effective solutions for preventing and treating various diseases. By leveraging their expertise in animal health, ImmuCell Corp aims to contribute to healthier livestock populations and more efficient farming practices.

7 analitičara trenutno ocenjuje akciju ImmuCell: 6 preporučuje kupovinu, 1 držanje i 0 prodaju. Za 2026 analitičari očekuju da ImmuCell ostvari prihod 15,14 М USD i zaradu po akciji -0,24 USD.

Po trenutnom kursu akcija ImmuCell kotira 10,38 EUR (11,42 USD).

Akcija ImmuCell (ICCC) kotira na 2 berze, uključujući: NASDAQ (ICCC), Frankfurt (IUL.F).

ImmuCell Corp is a US company specializing in the development and marketing of products for the prevention and treatment of animal diseases, particularly in the dairy industry. The company operates in two main divisions: animal health and veterinary diagnostics. In the animal health division, the flagship product is Calf-Guard®, an immunoglobulin preparation used for preventing diarrhea in calves. In the veterinary diagnostics division, the Bovine IgG Rapid Test Kit is a key product that allows farmers to monitor the health of their animals and detect diseases in a timely manner. ImmuCell Corp aims to expand its product pipeline and enter new markets.

očekivana prihod od ImmuCell je 15,14 М USD. Ova cifra je zasnovana na trenutnim finansijskim podacima i odražava poslovne rezultate preduzeća.

očekivana dobit od ImmuCell je -2,17 М USD. Neto dobit pokazuje profitabilnost preduzeća nakon odbitka svih troškova.

Odnos cene i zarade (KGV) za ImmuCell je trenutno -47,56. KGV poredi sadašnju cenu akcije sa zaradom po akciji i pomaže investitorima da procene valuaciju akcije ImmuCell.

Odnos cene i prihoda (KUV) za ImmuCell je trenutno 6,82. KUV poredi tržišnu kapitalizaciju sa godišnjim prihodima i služi kao metrika valuacije za akciju ImmuCell.

Eulpool score kvaliteta za ImmuCell je 3/10.

ISIN za ImmuCell je US4525253062. ISIN (International Securities Identification Number) je globalno jedinstveni identifikator za hartije od vrednosti.

WKN za ImmuCell je 885825. WKN (Wertpapierkennnummer) je šestocifreni nemački broj za identifikaciju hartija od vrednosti.

Ticker za ImmuCell je ICCC. Simbol tikera se koristi za trgovinu akcijama ImmuCell na berzanskom tržištu.

Фер вредностTerminal
11,31 USD
Над-/ПодцењеностTerminal
Адекватно вредна
Сектор
Индустрија
Биотехнологија
Број акција
Запослени
Приход по запосленом
378.687,33 USD
Раст прихода Ø5 година
Раст EBIT Ø5 година
Раст нето добити Ø5 година
Веб сајт immucell.com
Валута
USD
Јавна понуда
1. мај 1987.
ISIN
US4525253062
CUSIP
452525306
SEDOL
2457994
Тржишна капитализација
103,35 М USDMicro Cap
Опсег од 52 недеље
AAQS
3 / 10
PEG
—
P/E однос
P/Ee 2026
-47,56
P/Ee 2027
-103,77
P/S
P/Se
6,82
EV/EBIT
68,36
P/B однос
3,82
ROE (Поврат на капитал)
ROA (Поврат на имовину)
ROCE (Поврат на ангажовани капитал)
ROIC (Поврат на уложени капитал)
-2,58 %
Zadnje ažurirano 17. нов 2026. 09:23

ImmuCell Тикер

FRANKFURT · IUL.FNASDAQ · ICCC

ImmuCell FIGI

ICCC:US · BBG000BLQ5Q2ICCC:UA · BBG000BLQ6L5ICCC:UC · BBG000BLQ797ICCC:UN · BBG000BLQ8T3ICCC:UP · BBG000BLQ9W7ICCC:UB · BBG000BLQB89ICCC:UM · BBG000BLQCQ7ICCC:UX · BBG000BLQDF7ICCC:UR · BBG000BLQDY6ICCC:UD · BBG000BLQH68ICCC:UF · BBG000BLQJQ2ICCC:VY · BBG000BLQJX4

Sve ključne metrke i detaljne analize ImmuCell u dubinskoj analizi

Naša analiza akcija za akciju ImmuCell uključuje važne finansijske pokazatelje kao što su prihod, profit, P/E odnos, P/S odnos, EBIT, kao i informacije o dividendama. Takođe, razmatramo aspekte poput akcija, tržišne kapitalizacije, dugova, kapitala i obaveza kompanije ImmuCell. Ako tražite detaljnije informacije o ovim temama, na našim podstranicama vam nudimo opsežne analize: